- Clinical Trials
- April 2026
- 450 Pages
Global
From €4695EUR$5,000USD£3,917GBP
- Drug Pipelines
- April 2026
- 280 Pages
Global
From €2817EUR$3,000USD£2,350GBP
- Report
- March 2026
- 400 Pages
Global
From €4647EUR$4,949USD£3,877GBP
- Report
- April 2026
- 305 Pages
Global
From €2347EUR$2,500USD£1,958GBP
- Report
- January 2026
- 286 Pages
Global
From €2347EUR$2,500USD£1,958GBP
- Report
- August 2026
- 90 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- July 2026
- 160 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 150 Pages
Global
From €4554EUR$4,850USD£3,799GBP
- Report
- December 2025
- 150 Pages
Global
From €4554EUR$4,850USD£3,799GBP
- Report
- May 2026
- 150 Pages
Global
From €2534EUR$2,699USD£2,114GBP
- Report
- October 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- August 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- August 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- July 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- July 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- July 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- March 2026
- 135 Pages
Global
From €4554EUR$4,850USD£3,799GBP
- Report
- August 2026
- 70 Pages
Europe
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2026
- 150 Pages
United States
From €3755EUR$3,999USD£3,132GBP
- Report
- July 2026
- 80 Pages
Europe
From €4460EUR$4,750USD£3,721GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more